Australian Meningococcal Surveillance Programme, 1 April to 30 June 2016

The Australian Meningococcal Surveillance Programme monitors anticrobial resistance in the treatments for meningococcal infection. This quarterly report describes the results for theperiod 1 April to 30 June 2016.

Page last updated: 30 September 2016

Monica M Lahra, Rodney P Enriquez for the Australian Meningococcal Surveillance Programme

Introduction

The reference laboratories of the National Neisseria Network, Australia report laboratory data on invasive meningococcal disease (IMD) cases confirmed by laboratory testing using culture and non-culture based techniques for the Australian Meningococcal Surveillance Programme. Culture positive cases, where Neisseria meningitidis is grown from a normally sterile site or skin lesions, and non-culture based diagnoses, derived from results of nucleic acid amplification testing and serological techniques, are defined as IMD according to Public Health Laboratory Network definitions. Data contained in quarterly reports are usually restricted to a description of the numbers of cases by jurisdiction and serogroup, where known.

Results

Of note in this quarter 2016 is the number and proportion of IMD caused by serogroup W. In the years 2007 to 2011 the proportion of IMD caused by serogroup W in Australia ranged from 1.8% to 4.5%, and increased to 8.6% to 9.9% in 2013 to 2014. In 2015, this increased markedly to 31/81 (21.4%) of the IMD in Australia. In 2015, 25/31 serogroup W IMD strains were genotyped, and 81% were sequence type (ST)-11, and had the porA antigen encoding gene type P1.5,2, the same genotype as the hypervirulent serogroup W strain reported in the United Kingdom and South America since 2009. Nationally enhanced surveillance strategies, including whole genome sequencing and phylogenetic inference, has been applied to the recent emergence in Australia of N. meningitidis serogroup W in Australia.

Table: Number of laboratory confirmed cases of invasive meningococcal disease, Australia, 1 April to 30 June 2016, by serogroup and state or territory
State or territory Year Serogroup
A B C Y W135 ND All
Q2 YTD Q2 YTD Q2 YTD Q2 YTD Q2 YTD Q2 YTD Q2 YTD
Australian Capital Territory 2016 0 0 0 0 0 0 0 0 0 0 0 0 0 0
2015 0 0 1 1 0 0 0 0 0 0 0 0 1 1
New South Wales 2016 0 0 2 7 0 1 3 4 5 9 0 2 10 23
2015 0 0 9 12 0 1 2 2 1 2 1 1 13 18
Northern Territory 2016 0 0 2 2 0 0 0 0 0 0 0 0 2 2
2015 0 0 1 1 0 0 0 0 0 0 0 0 1 1
Queensland 2016 0 0 2 5 0 0 2 6 3 5 2 2 9 18
2015 0 0 4 9 0 0 0 1 0 0 1 1 5 11
South Australia 2016 0 0 5 11 0 0 0 0 0 0 0 0 5 11
2015 0 0 7 9 0 0 0 0 0 0 0 0 7 9
Tasmania 2016 0 0 0 0 0 0 0 0 0 2 0 0 0 2
2015 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Victoria 2016 0 0 4 7 0 1 2 2 9 15 0 0 15 25
2015 0 0 8 16 0 0 2 2 5 6 0 0 15 24
Western Australia 2016 0 0 1 2 0 0 0 0 1 3 0 0 2 5
2015 0 0 2 4 0 0 1 1 0 0 0 0 3 5
Total 2016 0 0 16 34 0 2 7 12 18 34 2 4 43 86
2015 0 0 32 52 0 1 5 6 6 8 2 2 45 69

Some minor corrections to data in the Table below may be made in subsequent reports if additional data are received. A full analysis of laboratory confirmed cases of IMD in each calendar year is contained in the AMSP annual report published in Communicable Diseases Intelligence. For more information see Commun Dis Intell 2016;40(1):E13.

Author details

Monica M Lahra1,2

Rodney P Enriquez 1

  1. Neisseria Reference Laboratory and World Health Organisation Collaborating Centre for STD, Sydney. Department of Microbiology, South Eastern Area Laboratory Services, The Prince of Wales Hospital, Randwick, NSW
  2. School of Medical Sciences, Faculty of Medicine, The University of New South Wales, New South Wales

Top of page

Communicable Diseases Intelligence subscriptions

Sign-up to email updates: Subscribe Now